FORTUNE 500

			Revenues		Profits
Rank	Company	Fortune 500 rank	$ millions	% change from 2009	$ millions	% change from 2009
1	Pfizer	31	67,809.0	35.6	8,257.0	-4.4
2	Johnson & Johnson	40	61,587.0	-0.5	13,334.0	8.7
3	Merck	53	45,987.0	67.7	861.0	-93.3
4	Abbott Laboratories	69	35,166.7	14.3	4,626.2	-19.5
5	Eli Lilly	115	23,076.0	5.7	5,069.5	17.1
6	Bristol-Myers Squibb	131	19,484.0	-9.9	3,102.0	-70.8
7	Amgen	163	15,053.0	2.8	4,627.0	0.5
8	Gilead Sciences	299	7,949.4	13.4	2,901.3	10.1
9	Mylan	418	5,450.5	7.0	345.1	48.4
10	Allergan	457	4,919.4	9.2	0.6	-99.9
11	Biogen Idec	476	4,716.4	7.7	1,005.3	3.6
12	Genzyme	487	4,535.9	0.5	422.1	-0.0

Rank	Company	Revenues %	Assets %	Stockholders' Equity %
1	Pfizer	12.2	4.2	9.4
2	Johnson & Johnson	21.7	13.0	23.6
3	Merck	1.9	0.8	1.6
4	Abbott Laboratories	13.2	7.8	20.7
5	Eli Lilly	22.0	16.4	40.8
6	Bristol-Myers Squibb	15.9	10.0	19.7
7	Amgen	30.7	10.6	19.3
8	Gilead Sciences	36.5	25.0	49.5
9	Mylan	6.3	3.0	9.6
10	Allergan	0.0	0.0	0.0
11	Biogen Idec	21.3	12.4	18.6
12	Genzyme	9.3	3.9	5.6

		Earnings Per Share	Total Return to Investors		Employees
Rank	Company	2000-2010 Annual growth (%)	2000-2010 Annual rate (%)	2010 (%)	Number	% change from 2009
1	Pfizer	5.6	-6.0	0.6	110,600	-5.1
2	Johnson & Johnson	10.9	4.0	-0.6	114,000	-1.3
3	Merck	-20.8	-5.3	2.8	94,000	-6.0
4	Abbott Laboratories	5.2	3.1	-8.2	91,440	25.5
5	Eli Lilly	5.1	-6.3	3.8	38,350	-5.0
6	Bristol-Myers Squibb	-2.7	-5.2	10.2	27,000	-3.6
7	Amgen	16.4	-1.5	-3.0	17,250	0.9
8	Gilead Sciences	N.A.	21.5	-16.2	4,000	3.3
9	Mylan	2.6	7.1	14.7	13,000	-7.1
10	Allergan	-45.4	4.4	9.3	9,200	10.8
11	Biogen Idec	44.4	0.6	25.3	4,850	2.1
12	Genzyme	8.8	4.7	45.3	10,100	-15.8